Clinical Trial Update: Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates subcutaneous golimumab added to DMARDs for rheumatoid arthritis, followed by an intravenous/subcutaneous golimumab strategy, and ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2012-12-07